Anti-PD-1 Antibody CDR Optimization for Binding Specificity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-PD-1 therapies, while effective in treating various cancers, may have limitations in specificity and durability of response, and there is a need for antibodies with enhanced binding and inhibitory activities to improve clinical outcomes.
Innovation Solution
Development of isolated antibodies or fragments specific to human programmed cell death protein 1 (PD-1) with optimized heavy and light chain complementarity determining regions (CDRs) that exhibit strong binding and inhibitory activities, including chimeric, humanized, or fully human antibodies with specific amino acid sequences, to enhance therapeutic efficacy.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current anti-PD-1 therapies are used, then cancer treatment effectiveness is improved, but binding specificity and durability of response are limited
Solution Approach 1:
The patent optimizes the complementarity determining regions (CDRs) of the antibody by modifying amino acid sequences in the variable domains. This changes the binding parameters of the antibody to PD-1, achieving both high specificity and prolonged durability of response. The optimized CDR sequences enable the antibody to maintain stable binding to PD-1 while distinguishing it from other proteins.
2Reliability
If anti-PD-1 antibodies are developed with enhanced binding activity, then therapeutic efficacy is improved, but antibody complexity increases
Solution Approach 1:
The patent applies local quality optimization by specifically modifying only the complementarity determining regions (CDRs) of the antibody while keeping the rest of the antibody structure intact. This allows enhancement of binding activity and therapeutic efficacy through localized sequence optimization without increasing overall antibody complexity. The framework regions remain standard, maintaining structural simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The antibodies demonstrate potent binding and inhibitory effects on PD-1, potentially leading to improved cancer treatment outcomes by modulating immune responses and enhancing the durability of therapeutic benefits.
Implementation Method 1
isolated antibodies or fragments specific to human programmed cell death protein 1 (PD-1) with optimized heavy and light chain complementarity determining regions (CDRs) that exhibit strong binding and inhibitory activities
Data Source
AI summary
Provided are anti-PD-1 antibodies or fragments thereof. Methods of using the antibodies or fragments thereof for treating and diagnosing diseases such as cancer, infection or immune disorders are also provided.